Skip to main content

Table 5 Resource Utilization among Cancer Patients with Empiric Fluconazole Antifungal Therapy by Treatment Failure

From: Fluconazole for empiric antifungal therapy in cancer patients with fever and neutropenia

  Treatment Failure No Treatment Failure Difference P R 2
N 42 61    
LOS, day      
   Unadjusted Mean (SE) 30.3 (1.9) 23.7 (1.5) 6.6 0.007  
   Median (range) 27 (8–73) 22 (4–55) 5.0   
   Adjusted Mean (SE) * 30.7 (1.6) 23.4 (1.3) 7.3 0.001 0.34
Total Costs per patient, $      
   Unadjusted Mean (SE) 71,122 (6,432) 55,234 (5,337) 15,888 0.060  
   Median (range) 56,924 (10,647–275,130) 47,642 (3,416–268,447) 9,282   
   Adjusted Mean (SE) * 72,921 (6,118) 53,996 (5,068) 18,925 0.020 0.18
  1. LOS, length of stay; SE, standard error;
  2. * Adjusted for age, gender, insurance status (uninsured or Medicaid), DRG weight and length of stay before empiric fluconazole therapy.